Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ARCH |
---|---|---|
09:32 ET | 800 | 2.14 |
09:36 ET | 400 | 2.15 |
09:39 ET | 100 | 2.15 |
09:41 ET | 600 | 2.14 |
10:28 ET | 100 | 2.15 |
10:39 ET | 100 | 2.15 |
10:42 ET | 100 | 2.14 |
10:48 ET | 500 | 2.13 |
11:08 ET | 600 | 2.15 |
11:09 ET | 2200 | 2.15 |
11:54 ET | 800 | 2.13 |
12:23 ET | 1100 | 2.11 |
01:35 ET | 500 | 2.11 |
01:39 ET | 100 | 2.11 |
01:51 ET | 4000 | 2.08 |
02:06 ET | 100 | 2.09 |
02:31 ET | 100 | 2.09 |
02:40 ET | 1000 | 2.06 |
03:12 ET | 7300 | 2 |
03:20 ET | 800 | 2.02 |
03:34 ET | 200 | 2.05 |
03:57 ET | 800 | 2.06 |
03:59 ET | 200 | 2.02 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arch Biopartners Inc | 127.0M | -64.8x | --- |
Medicenna Therapeutics Corp | 135.8M | -8.8x | --- |
Alpha Cognition Inc | 101.9M | -3.5x | --- |
NervGen Pharma Corp | 140.8M | -5.4x | --- |
Oncolytics Biotech Inc | 112.4M | -3.6x | --- |
Zentek Ltd | 145.7M | -12.1x | --- |
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $127.0M |
---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 62.9M |
Arch Biopartners Inc does not pay a dividend. | |
Beta | 0.98 |
EPS | $-0.03 |
Book Value | $-0.09 |
P/E Ratio | -64.8x |
Price/Sales (TTM) | 68.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -104.83% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.